Efficacy of Risankizumab across distinct PsA phenotypes identified with machine learning analytics using data from biologic DMARD-Naïve patients in two phase 3 clinical trials.

Abstract excerpt

BACKGROUND: The development of personalized approaches in psoriatic arthritis (PsA) is challenging due to unclear patient phenotypes and trajectories. Machine learning (ML) could help to identify homogeneous patient groups. The objective of this analysis was to classify patients with PsA into distinct phenotypes using ML. METHODS: A post hoc analysis of PsA patients treated with risankizumab for ≤ 4 years (196...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antibodies, Monoclonal
• Share to Antirheumatic Agents